After announcing in March that it was seeking “strategic alternatives” for its future, Seattle publicly-traded biotechnology company Neoleukin Therapeutics is now planning to merge with New York City-based Neurogene, a gene therapy startup.
In March, Neoleukin announced that it was discontinuing development of its computationally-designed immune therapy candidate and that CEO Jonathan Drachman was stepping down. The University of Washington spinout also slashed its workforce.
